Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
No single dietary approach proves universally superior
Well provide detailed aftercare instructions tailored to your specific treatment
Changes coming to weight loss drug coverage benefits, effective January 1, 2025 Effective January 1, 2025, Independence Blue Cross (IBX) will no longer offer coverage for drugs including glucagon-like peptide-1 receptor antagonist (GLP-1) and non-glucagon-like peptide-1 receptor antagonist (non-GLP-1) indicated for and prescribed solely for weight loss in the absence of other FDA-approved clinical indications
More people are choosing to support their body before symptoms appear instead of waiting until stress, fatigue, or toxin overload catches up
In summary, tirzepatide is the first dual receptor agonist that was recently approved for the treatment of T2D by the FDA
Naveed Sattar, a medical researcher and professor of metabolic medicine at the University of Glasgow, Scotland, said the results were "highly encouraging." "If Phase 3 results show similar gains and continued safety, MariTide, a drug with less frequent dosing requirements than current options, could be a very significant new treatment for people living with obesity and diabetes," Sattar said in a statement
